In a groundbreaking clinical trial, researchers at Imperial College London explore the potential of psilocybin, the active compound in magic mushrooms, to treat patients suffering from severe, treatment-resistant depression. By examining the brain's response to this psychedelic substance, the study aims to understand how it might disrupt the rigid patterns of thought associated with depression and offer a new path toward healing for those who have found no relief in traditional antidepressants.